Navigation Links
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer

cinomas carrying the erlotinib-resistant mutation EGFR L858R/T790M. These in vivo results suggest that AV-412 may exert potent clinical activity against non-small cell lung cancer tumors harboring EGFR L858R or EGFR L858R/T790M mutations.

About AV-412

AV-412 is a next generation oral tyrosine kinase inhibitor of EGFR/HER2 that could potentially treat patients with solid tumors. In preclinical studies, AV-412 has shown excellent activity in various tumor models, has a toxicity profile similar to other molecules in its class, and has shown preclinical activity against tumor cells that are resistant to first-generation tyrosine kinase inhibitors. The targets of AV-412 have been implicated in many significant human cancers including non-small cell lung cancer, metastatic breast cancer, pancreatic cancer, head and neck cancer and hormone refractory prostate cancer. AVEO's proprietary Human Response Prediction(TM) Platform offers an opportunity to exploit AV-412's unique characteristics and will provide further insight into potential clinical settings, tumor subtypes and responsive patient populations. AVEO acquired worldwide rights outside of Asia to AV-412 from Mitsubishi Pharma Corporation. For more information on the AV-412 clinical trial, visit www.clinicaltrials.gov and search using the keyword AV-412.

About AVEO

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction(TM) Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by Q3-2007 for AV-951, its oral, second-generation VEGF receptor inhibit
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:5/22/2013)... YORK , May 22, 2013 ... investigating potential claims on behalf of purchasers of ... the "Company") (NasdaqGS: AMAG -News).  The investigation focuses ... federal securities laws. On May 22, ... during intraday trading after the company announced in ...
(Date:5/22/2013)... , May 22, 2013   Accuray Incorporated ... management is scheduled to present at the 2013 Jefferies ... on Thursday, June 6, 2013 at 1:30 p.m. ... the presentation will be available online from the Investor ... The webcast replay of the presentation will ...
(Date:5/22/2013)... and MUNICH , May 22, 2013 ... and marketer of transcatheter aortic valve implantation (TAVI) systems for ... interim results of the J enaValve Eval U ation ... n Pa T ients with S E vere Ao R ... . JUPITER is a post-market registry to evaluate five-year ...
Breaking Medicine Technology:Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4
... VIVUS, Inc. (Nasdaq: VVUS ... (TA-303), a phase 3 clinical trial evaluating the safety ... treatment of erectile dysfunction (ED),will be presented this afternoon ... in Washington D.C.  The meeting is jointly sponsored by ...
... (NYSE: WPI ) today announced that its subsidiary, ... Food and Drug Administration (FDA) for Nabumetone Tablets USP, 500 ... shortly. Nabumetone had total U.S. sales of ... according to IMS Health.  Nabumetone is indicated for the relief ...
Cached Medicine Technology:Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 2Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 3Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 4Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 5Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 6Watson's Nabumetone Tablets Receive FDA Approval 2
(Date:5/22/2013)... York (PRWEB) May 22, 2013 Phelps ... established the Westchester Lung Nodule Center for individuals ... receive lung cancer care. Lung cancer is the deadliest form ... more people in the U.S. die from lung cancer than ... with all cancers, early detection increases survival rates. It ...
(Date:5/22/2013)... 2013 Registered Dietitian and Founder of Tatalou ... Tatalou.com sharing a recipe for making energy bars at home. ... Bars ,” takes a recipe modified from one recently ... “Every day it gets more and more difficult to understand ... “The size of the nutrition label continues to grow and ...
(Date:5/22/2013)... Georgia (PRWEB) May 22, 2013 HR ... event, hosted at the Gwinnett County Fairgrounds, on Friday ... company before, they far surpassed expectations; raising over $6,300 ... corporate sponsor for the event, donating the first $3,000 ... Beesley , challenged the internal staff to match the ...
(Date:5/22/2013)... May 22, 2013 Go Classy the ... announced the launch of their newest website http://www.Desire-Mexico.com ... of like minds, Desire Resorts have become the premier ... a feeling of total liberation while allowing you to ... COO of Go Classy Tours / Caribbean-Hideaways. He goes ...
(Date:5/22/2013)... News) -- In the aftermath of this week,s deadly tornado, ... for children and relatives, but also their pets. ... disaster and relocating to temporary housing can be stressful, but ... tips on how to ease that transition. One smart ... that can be used to help identify any animals displaced ...
Breaking Medicine News(10 mins):Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2Health News:Simple Steps Can Protect Pets in Weather Disasters 2
... , WEDNESDAY, May 26 (HealthDay News) -- Researchers report that ... the brain in mice -- a finding that could help ... who suffer from Alzheimer,s disease and stroke. , Removing clots ... blood to flow unimpeded, since blockages can lead to a ...
... Complete Genomics Inc., a third-generation human genome sequencing ... member of the Roche Group (SIX: RO, ROG; OTCQX: ... to sequence and compare a patient,s primary lung tumor ... researchers to compare the patient,s genome before and after ...
... are reporting development of a fast, simple, inexpensive method ... may cause skin allergies in people -- a method ... appears in ACS, Chemical Research in Toxicology , ... colleagues note the existence of public sentiment against the ...
... dramatically increased survival in the small group of patients who ... findings will be presented at the annual meeting of the ... June 4-8 in Chicago. Mayo oncologists say this new ... this rare cancer seems to be confined to the neck. ...
... undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning ... possible adverse side effects on oral health, according to a ... the American Dental Association (JADA). , Use of bisphosphonates ... osteonecrosis of the jaw (BON) that occurs spontaneously or after ...
... ... Center has become the first Community of Respect™ Medical Center in the Anti-Defamation ... ... Medical Center has become the first Community of Respect™ Medical Center in the ...
Cached Medicine News:Health News:Brain Cells May Serve as Clot-Busters 2Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2Health News:New treatment approach to rare cancer results in prolonged survival 2Health News:Some bisphosphonates users unfamiliar with drug's possible side effects on oral health 2Health News:Houston Northwest Medical Center Becomes First Hospital in the Southwest Region Designated a Community of Respect™ Partner 2
... Oscors proprietary quadripolar pacing wire ... pacing and sensing in the ... two bipolar wires in one ... the atrium and ventricle are ...
... Oscors proprietary quadripolar pacing ... consistent pacing and sensing in ... combining two bipolar wires in ... for the atrium and ventricle ...
... The TME 227 T ... used for temporary cardiac pacing ... open-heart surgery. The TME 227 ... in the myocardium, which allows ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: